(Q33411033)

26 July 2017

Phase I clinical trial of fludarabine phosphate (F-ara-AMP). (English)

1 reference

26 July 2017

phase I clinical trial

0 references

fludarabine phosphate

1 reference

E S Casper

1

1 reference

26 July 2017

A Mittelman

series ordinal

2

1 reference

26 July 2017

D Kelson

series ordinal

3

1 reference

26 July 2017

C W Young

series ordinal

4

1 reference

26 July 2017

1 January 1985

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

1 reference

26 July 2017

15

1 reference

26 July 2017

233-235

1 reference

26 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00263892

26 July 2017

0 references

cites work

Has the well gone dry? The First Cain Memorial Award Lecture.

1 reference

12 December 2020

Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine

1 reference

12 December 2020

Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin

1 reference

12 December 2020

Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin

1 reference

12 December 2020

Alterations in enzyme activity in tumors and the implications for chemotherapy

1 reference

12 December 2020

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite

1 reference

12 December 2020

METABOLIC EFFECTS OF 9-D-ARABINOSYLPURINES IN ASCITES TUMOR CELLS

1 reference

12 December 2020

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase

1 reference

12 December 2020

The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A).

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00263892

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference